PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS

医学 内科学 阿糖胞苷 威尼斯人 髓系白血病 髓样 白血病 胃肠病学 移植 肿瘤科 阿扎胞苷 低甲基化剂 外科 慢性淋巴细胞白血病 生物化学 基因表达 化学 DNA甲基化 基因
作者
Sabine Käyser,Khaled Sanber,Giovanni Marconi,Alexandra L. Mattei,Marlise R. Luskin,Amar H. Kelkar,Marco Cerrano,Chiara Sartor,Fabio Giglio,Marta Riva,Lorenzo Rizzo,Francesco Saraceni,Selene Guerzoni,Federica Lessi,Erika Borlenghi,Alexander E. Perl,Mark J. Levis,Cristina Papayannidis,Tania Jain,Richard F. Schlenk
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e1610525-e1610525
标识
DOI:10.1097/01.hs9.0000974204.16105.25
摘要

Topic: 4. Acute myeloid leukemia - Clinical Background: Extramedullary (EM) manifestations of acute myeloid leukemia (AML) are rare, but have a broad clinical spectrum. EM has traditionally been approached with conventional chemotherapy (CTX) and/or radiation. Recently, venetoclax (VEN) in combination with hypomethylating agents (HMA) or low-dose cytarabine was approved for treatment of newly diagnosed AML patients (pts) who are ≥ 75 years or who are ineligible for intensive CTX due to comorbidity. Whether EM AML responds to VEN/HMA is not known. Aims: To characterize adult pts with EM AML and evaluate outcome after VEN/HMA treatment within an international retrospective cohort analysis. Methods: We studied 41 pts (median age, 66 years; range, 19-81 years) treated with VEN/HMA between 2017 and 2022. Eighteen (44%) of 41 pts were relapsed or refractory after intensive CTX or allogeneic hematopoietic stem cell transplantation (allo-HCT; n=10/18) prior to VEN/HMA. Up to 31 VEN/HMA cycles (median, 2 cycles; ≤2 cycles, n=23; 3-4 cycles, n=10; ≥5 cycles, n=8) were administered according to the previously approved regimens. EM response assessment was performed by CT or PET-CT and bone marrow (BM) and/or cerebral fluid/MRI evaluation in case of central nervous system involvement. Results: Type of AML was de novo in 23 (56%), secondary after myelodysplastic syndrome/myeloproliferative neoplasm in 17 (41%), and therapy-related in 1 (3%) patient. Median white blood cell and platelet counts at time of EM presentation were 6.6/nl (range, 0.6-131.2/nl) and 66/nl (range, 6-307/nl), respectively. Fifteen pts (37%) were female; ECOG was ≤2 in all pts. Overall, pts had in median 2 EM manifestations (range, 1-5; Table 1). In addition to EM disease, n=34 (83%) pts had BM involvement. Cytogenetic analysis was performed in 38 (93%) pts. Seventeen (45%) pts showed a complex karyotype, 9 (24%) a normal karyotype and 12 (31%) pts other abnormalities. NPM1 was mutated in 8 (20%) and 3 (7%) pts had a FLT3-ITD mutation. TP53 and spliceosomal mutations could be detected in 11 (27%), each. Risk classification according to ELN 2022 was low-risk in 5 (12%), intermediate-risk in 13 (32%) and high-risk in 20 (49%) of the pts (missing, n=3; 7%). Eighteen (44%) pts achieved CR/CRi after VEN/HMA treatment, of whom 3 were heavily pretreated including allo-HCT. Five (12%) pts achieved a partial remission (PR) and 4 (10%) stable disease. The overall response rate (ORR; including CR/CRi/PR) was 56% (n=23). Six pts went on to allo-HCT (CR/CRi, n=4; PR, n=2). Prior to allo-HCT all pts received ≤4 cycles (2 cycles, n=3; 1/3/4 cycles, n=1, each). Conditioning was dose-reduced in 4 and myelo-ablative in 2 pts. Median follow-up was 28.8 months (95%-CI, 11.5 months - not reached) and median overall survival (OS) 6.4 months (95%-CI, 3.9-12 months). One-year and 2-years OS rates were 26.4% (95%-CI, 15-47%) and 14% (95%-CI, 5-36%), respectively. Age with a cut-off of 60 years had no impact on OS (P=0.80). Relapse occurred in 11 of 18 (61%) pts who had achieved CR/CRi after VEN/HMA treatment. Of those, all except than two succumbed of their disease. Five (28%) pts are in ongoing CR/CRi and 2 died in CR. All pts who did not respond died due to disease progression. Summary/Conclusion: In our group of pts with high-risk features, treatment with VEN/HMA resulted in an encouraging ORR of 56% with a CR/CRi rate of 44%. However, VEN/HMA alone may not be effective in maintaining disease control. Whether allo-HCT after disease control with VEN/HMA is a veritable option needs to be evaluated in the future.Keywords: Acute myeloid leukemia, Venetoclax, Clinical outcome

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陌路完成签到,获得积分10
刚刚
隐形曼青的应助被angelcynthia采纳,获得10
刚刚
刚刚
幻城完成签到,获得积分10
1秒前
传奇3的应助被恭雖采纳,获得10
1秒前
54188完成签到,获得积分10
1秒前
科研老白完成签到,获得积分10
1秒前
科研顺利发布了新的文献求助10
2秒前
秋语芙完成签到,获得积分10
2秒前
Akim的应助被敏感烤鸡采纳,获得10
2秒前
blablawindy发布了新的文献求助10
2秒前
情怀的应助被季夏初拾采纳,获得10
2秒前
rong774完成签到,获得积分10
3秒前
3秒前
多吃青菜发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
orange发布了新的文献求助20
4秒前
4秒前
海拾月发布了新的文献求助10
4秒前
4秒前
酷波er的应助被木今采纳,获得10
4秒前
哈哈哈发布了新的文献求助10
4秒前
cyyyyer发布了新的文献求助10
4秒前
VANNIE完成签到 ,获得积分10
5秒前
5秒前
5秒前
Hello的应助被乖猫要努力采纳,获得10
5秒前
5秒前
5秒前
6秒前
QingYe发布了新的文献求助10
6秒前
落后的滑板完成签到,获得积分10
6秒前
Layqiwook发布了新的文献求助10
7秒前
8秒前
Ciaoh发布了新的文献求助10
8秒前
8秒前
赘婿的应助被贺贺采纳,获得10
8秒前
天天快乐的应助被兜兜想哒哒采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155187
求助须知:如何正确求助?哪些是违规求助? 9551559
关于积分的说明 21705535
捐赠科研通 7744381
什么是DOI,文献DOI怎么找? 3426041
关于科研通互助平台的介绍 2551144
邀请新用户注册赠送积分活动 2469770